Evidence map›Paper›PMID 41939836›Full record

ArticleFrontiers in pharmacology2026

Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis.

Zhixiang Wu, Yanjuan He, Hao Deng, Yue Tan, Wangzi Gao, Jiaxin Yin, Ziqin Zeng, Jing Sun, Lijuan Zhang, Yue Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhixiang WuDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
Yanjuan HeDepartment of Pediatrics, The Fourth Hospital of Changsha, Changsha Hospital of Hunan Normal University, Changsha, China.
Hao DengHunan Normal University School of Medicine, Changsha, China.
Yue TanHunan Normal University School of Medicine, Changsha, China.
Wangzi GaoHunan Normal University School of Medicine, Changsha, China.
Jiaxin YinHunan Normal University School of Medicine, Changsha, China.
Ziqin ZengHunan Normal University School of Medicine, Changsha, China.
Jing SunDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
Lijuan ZhangDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
Yue LiDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
Shentang LiDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD), whose prevalence is rising substantially, has become a major global health challenge. In this study, we developed linagliptin-loaded chitosan nanoparticles (HCS-LGP NPs) for the treatment of renal fibrosis. The synthesized nanoparticles exhibited a uniform particle size of 178.8 ± 4.4 nm and a zeta potential of -29.9 ± 2.5 mV, along with acid-responsive drug release properties.

Indexed as

anti-renal fibrosisbiocompatibilitychitosan nanoparticleschronickidney diseasedipeptidyl peptidase-4 inhibitordrug delivery systemlinagliptinnano-delivery carrier

Identifiers

PMID41939836
PMCPMC13043646

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.